Discuss your imaging options with your Referring Physician, or feel free to call us here at ADR if you have any questions about our services. Providers must read the entire NCD and related Internet Only Manual (IOM) sections (see "Sources" at end of this article) in order to correctly understand and apply the following coding guidance. , [18 F]-DCFPyL was approved by the Food and Drug Administration (FDA) in May 2021 and is commercially available as PYLARIFY ® (Piflufolastat F 18 Injection) and sold by Lantheus. GoodRx coupons are not available at HCP offices for these medications, but there might be other ways you can save on. There are more than 800 board-certified specialty physicians across the Providence network treating patients with every type of cancer. High-yield savings accounts. Pylarify; Descriptions. Meanwhile, the CT scan uses x-rays to show the organs and tissues. O’Fallon (618) 416-7970. PYLARIFY ® (Piflufolastat F18. For non-UCSF facilities referring patients that are new to UCSF, please fax the following to (415) 353-7299 for patient registration to. The company only. PYLARIFY® is a clear, colorless solution; PYLARIFY® may be diluted with 0. Additionally, there is some overlap with prebiopsy. PYLARIFY® may help detect metastases even when PSA levels are low. UCLA is not charging the $ 3,300. PYLARIFY will be available immediately to imaging centers in parts of the mid-Atlantic and southern regions and is expected to be broadly available throughout the U. 00 for the Pylarify PET/CT. The deep inguinal lymph nodes are within the femoral sheath medial to the femoral vein. Organic chemists can tell a lot about a molecule by the. of Employees: 6. The lymphatic drainage patterns of urogenital malignancies are complex in the pelvis; however, spread from the pelvic organs to the medial chain of the external iliac nodal group is the most common route through which. PYLARIFY PSMA - Where and when. Then you have Gallium PSMA, which is limited to UCLA [University of California, Los Angeles] and UCSF [University of California, San Francisco]. hospital outpatient departments. The superficial inguinal lymph nodes drain the anal canal (below the pectinate line), the skin below the umbilicus, lower extremity, scrotum, and vulva. Pylarify, made by Progenics pharmaceuticals, is. • Assay the dose in a suitable dose calibrator prior to administration. • Dispose of any unused PYLARIFY in compliance with applicable regulations. Administered every 6 weeks for up to 6. 45%. With 3 million men living with prostate cancer and more than 18. January 2024 Alpha-Numeric HCPCS Files (ZIP) - Updated 11/21/2023. 9h ago. . This article describes the least restrictive coverage possible. 1 year ago • 15 Replies. The resource-based relative value scale (RBRVS) is the physician payment system used by the Centers for Medicare & Medicaid Services (CMS) and most other payers. 9% sodium chloride injection USP. PSMA-targeting radiotracers, including a small molecule-based agent developed at Johns Hopkins. 9% Sodium Chloride Injection, USP. All Drugs; Human Drugs; Animal Drugs. PYLARIFY ® (piflufolastat F 18) injection (also known as 18 F-DCFPyL or PyL) is a fluorinated small molecule PSMA-targeted PET imaging agent that enables visualization of lymph nodes, bone and. Ingredients. 29. Money market accounts. (NASDAQ:LNTH) Q3 2023 Earnings Call Transcript November 3, 2023 Operator: Good morning. Whole Body $3,300 – $12,000. read more , diabetes Diabetes Mellitus (DM) Diabetes mellitus is. 26732 Crown Valley Pkwy, Suite 171, Mission Viejo, CA 92691. Vulvar Cancer Version 2. PYLARIFY is a sterile, non-pyrogenic, clear, colorless solution for intravenous injection. Introduction [18 F] 2-fluoro-2deoxy-D-glucose (18 F-FDG) PET-CT imaging has become firmly established as an excellent clinical tool in the diagnosis, staging and restaging of cancer. 803-296-3100. PYLARIFY AI™ (aPROMISE). 12. You can renew prescriptions, send messages, and schedule appointments – all. By targeting PSMA, PYLARIFY® can give your doctor a clear image and additional information on the location and extent of the cancer. 2161 Kingsley Ave, Ste 100. 5 to 7. 8, and 3. 2217. If you need help understanding your options, enrolling, or managing your plan, a Florida Blue agent is here for you. Fortune. The ability to combine functional and anatomical information has equipped PET/CT to look into various aspects of lung cancer, allowing more precise disease staging and providing useful data during the. Indication. Life-saving advancements from companies like Lantheus Holdings (NASDAQ:. Send Email to Patient Portal Support. ”. During this time of uncertainty, Humana continues to invest in. However, no abnormal activity was noted in the right lung. This drug is administered by your healthcare practitioner (HCP), which usually means: It may be expensive. 7 million and a profit of $7. ADVISORY COMMITTEE : Your application for PYLARIFY was not referred to an FDA advisory committee because thisThe NCCN has added Ga 68– and F 18–based PSMA-PET imaging modalities to its clinical practice guidelines for prostate cancer. May 27, 2021 — Today, the FDA approved the 18F-DCFPyL PSMA PET imaging agent (also known as “PyL” for short or by its trade name “PYLARIFY”). Cancer is in two lymph nodes near to one another and on the same side of the body, or the cancer is in one organ and nearby lymph. This scan is used to diagnose cancer in the prostate gland. Our surgeons are also highly experienced in a procedure called salvage radical prostatectomy. PYLARIFY may be diluted with 0. For example, shares gapped up 11% in November of last year following the company's quarterly report. OUR LOCATION Visit Our Convenient and State of the Art Medical Imaging Center in Santa Monica. Manufacturing, Supply Chain and Distribution Capabilities Deep experience dealing with complex radiopharmaceuticals: Both imaging and therapy radioligands –short-lived and long-lived. • Dispose of any unused PYLARIFY in compliance with applicable regulations. 00 anymore and it is billing Medicare and secondary insurances for part B. PYLARIFY® is an imaging agent for PET/CT scans that uses a unique combination of a PSMA-targeted small molecule and the radioactive tracer 18 F to help your doctor make more informed treatment choices based on clear images. As the levels of PSAPylarify is supplied as a 50mL multiple-dose glass vial containing 37 MBq/mL to 2960 MBq/mL (1 mCi/mL to 80 mCi/mL) of piflufolastat F 18. 3 million from the prior year period. Additional coverage policies may be developed as needed or may be withdrawn from use. Health Canada. To reduce the risk of kidney and. , Nov. PYLARIFY® (piflufolastat F 18) injection is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: with suspected metastasis. Indication PYLARIFY® (piflufolastat F 18) Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA). In the OSPREY trial the Pylarify PET/CT detected metastatic disease in 58% (19 of 33) of men with advanced cancer who were negative for metastases on conventional CT and bone scanning. News release. Online checking accounts. Ureteral cancer is uncommon. 9% Sodium Chloride Injection, USP. 0. PYLARIFY is a drug used for detection of specific cancer lesions in patients with prostate cancer. Pylarify PET Scan ($7,900) Ga-68 PSMA Illucix Scan ($7,650) Our Location. 5 million Medicare Advantage members. 8 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. Helical (spiral) CT scans, with or without. Side effects of Pylarify include: headache, changes in taste, and. The incidence of prostate cancer increases with patient age, with an incidence rate of 1 in 350 men for those under 50 years of age, climbing to an incidence of 60% in men over the age of 65. Frederic Pouliot, Hospitalier Universitaire (CHU) de Québec-Université Laval. Lantheus Holdings, Inc. The pH of the solution is 4. The PYLARIFY® patient brochure includes information on prostate cancer, an overview of how PYLARIFY® can help you and your doctor create an optimal treatment plan, as well. Purpose: 18F-fluorodeoxyglucose (FDG) PET/CT is invaluable in managing liver lesions, in particular in the evaluation of suspected liver metastases. 5 to 7. 9 % $ 621,419 $ 366,763 . PSA in the blood is measured in units called nanograms per milliliter (ng/mL). 1611 NW 12th Ave. 4 million in the prior year period; GAAP fully diluted net loss of $0. Myocardial imaging, positron emission tomography (PET), perfusion study (including ventricular wall motion[s] and/or ejection fraction[s], when performed); single study, at rest or stress (exercise or2022-2023 Radiopharmaceutical Fee Schedule. The June 2021 release of Pylarify set in motion a new series of price increases. 78430 . Medicare did not pay for the Pylarify used in PSMA PET/CT Scan; Any benefits from a Choline C-11 Scan in addition to Pylarify PSMA PET MRI? If insurance denies PSMA PET coverage for an approved use, appeal! PSMA to possibly be FDA approved in Dec. To find the most recent Medical Necessity Review list, precertification policies, and modifiers and reimbursement policies. Cancer of the ureter (ureteral cancer) is an abnormal growth of cells on the inside lining of the tubes (ureters) that connect your kidneys to your bladder. 01 µg/mCi of piflufolastat at calibration time and date, and ≤ 78. The official update of the HCPCS code system is available as a public use file below. It will need to spend additional. Heart $2,850 – $24,200. 5 million. Kerendia. S. Don’t forget about home decor in the private space of your bedroom and bath zones. “PYLARIFY has the potential to contribute meaningful and actionable information that can be used to personalize treatment plans in men with low PSA levels,” said Dr. Oliver Sartor, MD. There are several types of PET Scans, and it is important that you follow the preparations your scan. 9h ago. Brain $2,250 – $10,700. Morris, MD, discusses the choice between the 2 FDA-approved PSMA-PET imaging agents—and piflufolastat F 18 (18F-DCFPyL; Pylarify) and Gallium 68 PSMA-11 (Ga 68 PSMA-11)—for managing patients with prostate cancer. A sample CMS-1500 claim form for billing PYLARIFY® is provided below. Phone numbers must be entered on all dose orders. S. It targets a. A PET-CT is a painless imaging scan that can detect cancer and certain heart and brain diseases. Find your nearest center to order PYLARIFY® for PET/CT scans, as well as downloadable resources and reimbursement support inf. I have a $220,000 mortgage. Santa Monica Breast Center. PYLARIFY® FOR PCa IMAGING; EFFICACY AND SAFETY. ac61418 •. In addition to clinical drug information, FDB publishes several drug pricing data fields, including: FDB discontinued the publication of Blue Book Average Wholesale Price (AWP) on September. Prescription only. S. Ga 68 PSMA-11 and Pylarify (piflufolastat F 18) were approved by the FDA in 2020 and 2021, respectively. Our products have practical applications in oncology, cardiology and more. 1007/s00261-013-0043-3. PYLARIFY uptake is not specific for prostate cancer and may occur with other types of cancer as well as non-malignant processes and in normal tissues. Follow the PYLARIFY® injection with an intravenous flush of 0. The deep nodes receive drainage from the glans penis or clitoris, as well as the superficial lymph nodes. Efficacy: High-risk PCa: OSPREY COHORT A; Efficacy: Biochemically Recurrent PCa: CONDOR; Efficacy: Locally Recurrent or New/Progressive PCa: OSPREY COHORT B; Safety; CASE STUDIES; HOW TO USE PYLARIFY® REIMBURSEMENT AND AVAILABILITY; PYLARIFY AI™ PYLARIFY AI™ Overview; What Is PYLARIFY AI™? References. Take a 360 tour of our labor & delivery suites. Post Administration Instructions • Follow the PYLARIFY injection with an intravenous flush of 0. November 29, 2021 08:30 ET | Source: Lantheus Holdings, Inc. PYLARIFY is a radioactive drug, which will increase lifetime radiation exposure. 1. 11/30. LOCAMETZ ® (kit for the preparation of gallium Ga 68 gozetotide injection), after radiolabeling with gallium-68, is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy. by year endNORTH BILLERICA, Mass. Your doctor, hospital, or clinic will provide this medication. Each milliliter contains 37 to 2,960 MBq (1 to 80 mCi) piflufolastat F 18 with ≤0. Do not eat foods with more than 5g of carbohydrates per serving, no more than 15g of carbohydrates per meal and no more than 50g of carbohydrates per day. Locations. You cannot fill this prescription in a regular pharmacy. Dana-Farber Cancer Institute in Boston, MA, is a world leader in adult and pediatric cancer treatment and research. Your MITS provider will use your medical history and blood test results to decide when to start your Pluvicto treatment. PDF Version. Radiology includes a variety of imaging tests — from MRI to minimally invasive interventional radiology. Molecular imaging with positron emission tomography. PYLARIFY® CODING AND BILLING GUIDE | PYLARIFY® Reimbursement Hotline: 844-339-8514 PYLARIFY® and the associated services provided in a physician office are billed on the CMS-1500 claim form or its electronic equivalent. Axumin: Some background: FDG was the most widely used scan type, but it relies on a particular biological process (Warburg effect, if you must know — the “high glycolytic effect” mentioned in article) that most PC cells do not undergo, so uptake was limited. 45%. Personalize QR Codes and promote your products and services on your socials or in person. Penile Cancer Version 1. One unit of service will be allowed for A9503. Pylarify specifically is a radionuclide tracer. Click the link below to view a short video on the Patient Portal. The doctor’s office will process any payments related to your visit and treatment. 11/11/2022. Deposit products offered by Wells Fargo Bank, N. PYLARIFY PET/CT scan could interpret your results incorrectly. Billerica, MA), for. Gross anatomy. C/O Patient Name and Room Number (if known) 1000 Johnson Ferry Road. Be registered as a VA Patient in My HealtheVet. See the Consumer Account Fee and Information Schedule and Deposit Account Agreement for additional consumer account information. It ensures that high-quality health services are accessible, and works to reduce health risks. Oliver Sartor, MD. This drug is likely to be covered under your medical benefit if you have insurance. Answers to Chapter 1 Practice Questions. Best for Savings Rates. About PYLARIFY ® (piflufolastat F 18) Injection PYLARIFY ® (piflufolastat F 18) injection (also known as 18 F-DCFPyL or PyL) is a fluorinated small molecule PSMA-targeted PET imaging agent that enables visualization of lymph nodes, bone and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate. PYLARIFY Injection is designed to detect prostate-specific membrane. fatigue. Pylarify = 18F-DCFPyL, mentioned above. GAAP fully diluted earnings per share. PYLARIFY is a sterile, non-pyrogenic, clear, colorless solution for intravenous injection. The combined PET/CT scan joins these two technologies together. Efficacy: High-risk PCa: OSPREY COHORT A; Efficacy: Biochemically Recurrent PCa: CONDOR; Efficacy:. NCCN Category 2A designation supports coverage of IGH and TP53 gene testing for Chronic Lymphocytic Leukemia (CLL) patients. ILLUCCIX, after radiolabeling with GA 68, is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: With suspected metastasis who are candidates for initial definitive therapy. Used mostly in patients with brain or heart conditions and cancer, PET helps to visualize the biochemical changes taking place in. I am inspired by the life-saving impact of the work that I do each and every day. Forgot your password? Request WebOLO Account. Lantheus receives US FDA approval of Pylarify (piflufolastat F 18) injection, the first and only commercially available PSMA PET imaging agent for prostate cancer. Saving $1 million (or more) for retirement is a great goal to have. PYLARIFY ® (piflufolastat F 18) Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy. Doctors use nuclear medicine to diagnose, evaluate, and treat various diseases. The U. JM Provider Enrollment Open House: December 5, 2023 Registration. Pylarify specifically is a radionuclide tracer. Password. PYLARIFY ® (piflufolastat F 18) Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men. July 2023 Alpha-Numeric HCPCS File (ZIP) -. The pH of the solution is 4. Piflufolastat F 18 injection is used with a PET scan (positron emission tomography) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer. 5757 W Thunderbird Rd Suite W101. Received the EOB for my Pylarify PSMA scan. PYLARIFY® FOR PCa IMAGING; EFFICACY AND SAFETY. 6%. Your doctor, hospital, or clinic will provide this medication. In the press release they say it will be available immediately to imaging centers in parts of the mid-Atlantic and southern regions and is expected to be broadly available throughout the US by year end. Drug Trials Snapshots is part of an overall FDA effort to make demographic data more available and transparent. Prostate cancer is the most common non-dermatologic cancer in men, and the second leading cause of cancer-related death. 00. Resonance structures can also be non-equivalent. -1. Generic & Biosimilar Medicines Savings Report. Orange Park, FL 32073. Learn about our imaging services at the University of Miami Health System. The collaboration with Novartis directly. It’s important that the medicine you take is safe and effective. IMPORTANT SAFETY INFORMATION. 68. User Name. • Calculate the necessary volume to administer based on calibration time and required dose. Reno, Nevada (UroToday. CC-BY-4. If approved for Europe, PYLCLARI ® (INN: Piflufolastat (18 F) formerly known as [18 F]-DCFPyL) will offer prostate cancer patients access to a diagnostic imaging agent more sensitive than conventional imaging. National Range: $1,250 – $9,225+. Generic and Biosimilar Drugs Generate $408 Billion in Savings for America’s Patients and Healthcare System in 2022 Washington, DC—On September 6, 2023, the Association for Accessible Medicines, the leading trade association for generic and biosimilar manufacturers, released its 2023 U. Hot Topic Tuesday Teleconference: November 28, 2023 Register - 3 Days Left. Compare Prices Specify your dosage and quantity to find out exactly how much you can save. PYLARIFY AI is intended to be used by healthcare professionals and researchers for acceptance, transfer, storage, image display, manipulation, quantification and reporting of digital medical images. uni-rostock. DULLES, Va. 51% for 90 days. The platform. PYLARIFY® (Piflufolastat F 18 Injection) and sold by Lantheus. 2024. Abstract. [1] [4] [5] It is. You’ll see how much the patient pays with Original Medicare and no supplement (Medigap) policy. , according to doc at UCLA; Moderation team. The Veterans Advantage card allows you to shop a private Dell store online. PYLARIFY PET/CT with PSMA Tracer. PYLARIFY ® (piflufolastat F 18) injection (also known as 18 F-DCFPyL or PyL) is a fluorinated small molecule PSMA-targeted PET imaging agent that enables visualization of lymph nodes, bone and. This drug is likely to be covered under your medical benefit if you have insurance. , a Novartis company) for the treatment of. , A Siemens Healthineers Company, supports the growth of our customers' business with on-time delivery of PET tracers and comprehensive value-added services. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider. 1 Standardized PSMA PET reporting provides consistent and precise disease. FDA-Approved Drugs in 2020. In the U. WARNINGS . The specific benefits subject to prior authorization may. This document. Indication. --(BUSINESS WIRE)--May 27, 2021-- Lantheus Holdings, Inc. 9% Sodium Chloride Injection, USP. We would like to show you a description here but the site won’t allow us. Use of standardized procedures will increase the applicability of clinical research among multiple institutions, in turn, increasing the value of research studies, particularly. 01 µg/mCi of piflufolastat at calibration time and date, and ≤ 78. Each milliliter contains 37 to 2,960 MBq (1 to 80 mCi) piflufolastat F 18 with ≤0. PYLARIFY AI is an FDA-cleared artificial intelligence platform developed to assist in standardized quantification of PSMA PET/CT scans. Tel: (904) 276-2303. I’m 58 With $700k in Retirement Savings, But I Won’t Collect Social Security for 7 Years appeared first on SmartReads by SmartAsset. S. The idea with PET scan is that cancerous tissues will be more. This year’s theme, Leading Through. We’ve made it easy to start selling with Payify. Here you will find links to several key resources for health care professionals to help your practice perform efficiently and make it easier to do business with Cigna. krause@med. Thymomas and Thymic Carcinomas Version 1. (the “Company”) (NASDAQ: LNTH), an established leader and fully. 220. SoFi members with Direct Deposit or $5,000 or more in Qualifying Deposits during the 30-Day Evaluation Period can earn 4. • PYLARIFY seems to be affected by the amount (level) of PSA in your blood. 00. finerenone. Your diagnostic imaging is done locally, and fellowship-trained specialists in their field of expertise read the results, so you'll get a fast, accurate diagnosis. PYLARIFY may be diluted with 0. Consult the nuclear medicine physician if the patient is diabetic. doi: 10. News & World Report. (NASDAQ:LNTH) Q3 2023 Earnings Call Transcript November 3, 2023 Operator: Good morning. with. PYLARIFY AI is an FDA-cleared artificial intelligence platform developed to assist in standardized quantification of PSMA PET/CT scans. Non-equivalent Resonance Structures. About PYLARIFY ® (piflufolastat F 18) Injection PYLARIFY ® (piflufolastat F 18) injection (also known as 18 F-DCFPyL or PyL) is a fluorinated small molecule PSMA-targeted PET imaging agent that enables visualization of lymph nodes, bone and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate. Please read the disclaimer. Tell your doctor if you or your child. Image interpretation errors can occur with Axumin PET. The procedure standards will help to identify those elements of the procedure that are most important in obtaining a high-quality examination, while simultaneously controlling costs. The approval covers the use of Lu177-PSMA-617 in patients who have metastatic prostate cancer that is hormone-resistant (also known as castrate-resistant) and whose tumors. The company reported that over 1,000 customers have ordered PYLARIFY, with a repeat order rate of 97%. It seems that the approved Medicare payment will be $ 5,224. 29, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. Three-dimensional (3D) rendering. Enter your email to sign up. 1. 1. 4 GBq (200 mCi) of radioactivity at the date and time of administration. 5 million. 4 million for the third quarter 2021, compared to GAAP net loss of $6. PYLARIFY is a sterile, non-pyrogenic, clear, colorless solution for intravenous injection. Figure 1. Medicare did not pay for the Pylarify used in PSMA PET/CT Scan. LoginDOI: 10. 00 thru 2/28/21. Seek medical care or call 911 at once if you have the following serious side effects: Serious eye symptoms such as sudden vision loss, blurred vision, tunnel vision, eye pain or swelling, or seeing halos around lights;The National Comprehensive Cancer Network (NCCN) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI) have now updated their guidelines to allow use of Pylarify PSMA PET to qualify for Pluvicto (177Lu-PSMA617). 9 mg ethanol in 0. A prostate-specific membrane antigen (PSMA) positron emission tomography (PET) scan is a new type of nuclear medicine procedure for men with prostate cancer. the terms of the applicable coverage plan document in effect on the date of service. U. 73 m 2 BSA ( chronic kidney disease Chronic Kidney Disease Chronic kidney disease (CKD) is long-standing, progressive deterioration of renal function. [Melbourne, Australia], and Novartis/AAA, respectively) should be considered equivalent for selection of patients for. Food and Drug Administration. 6-10 PYLARIFY ® (piflufolastat F. INDICATION. NORTH BILLERICA, Mass. 4. The system is intended to be used with images acquired using nuclear medicine (NM) imaging using PSMA. PYLARIFY® (piflufolastat F 18) Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy. . It’s also one of the first tests done in men who have symptoms that might be caused by prostate cancer. The performance of PYLARIFY for imaging of patients with biochemical evidence of recurrence of prostate cancer seems to be affected by serum PSA levels. The cancer cells appear as big spots in the PET scan. 7 mi. Our wellness center offers a spa-like. To qualify for Pluvicto, one needs a positive PSMA PET scan, but. The device provides general. Covered Drugs. Effective date is noted in the file title. N/A. NORTH BILLERICA, Mass. PYLARIFY AI is intended to be used by healthcare professionals and researchers for acceptance, transfer, storage, image display, manipulation, quantification and reporting of digital medical images. IMG 5012. November 29, 2021 08:30 ET | Source: Lantheus Holdings, Inc. --(BUSINESS WIRE)--May 27, 2021-- Lantheus Holdings, Inc. Pylarify = 18F-DCFPyL, mentioned above Axumin : Some background: FDG was the most widely used scan type, but it relies on a particular biological process (Warburg effect, if you must know — the “high glycolytic effect” mentioned in article) that most PC cells do not undergo, so uptake was limited. PYLARIFY ® (piflufolastat F 18) Injection Indication PYLARIFY ® (piflufolastat F 18) Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer:. Pylarify sales have exploded since the product launched, reaching $232 million in the first six months of 2022. The healthcare company released its quarterly results on Thursday, surpassing analysts' forecasts for revenue and earnings. 81. For the full year 2022, Lantheus forecasts PYLARIFY to be in a range of $300M to $325M and their. 949-364-6900. This dataset provides data for wholesale acquisition cost (WAC) increases that exceed the statutorily-mandated WAC increase threshold of a 16% increase for the period including the current quarter and the previous two calendar years for prescription drug products with a WAC greater than $40 for a course of therapy.